Washington Post Publisher Will Lewis Steps Down After Layoffs 
Thailand Inflation Remains Negative for 10th Straight Month in January 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions 
Celltrion announced that its COVID-19 test kit called DiaTrust has been given conditional approval by South Korea’s drug safety board. The biopharmaceutical company headquartered in Incheon shared the news on Monday, April 3.
The new coronavirus test kit
The Korea Herald reported that DiaTrust was jointly developed by Celltrion and Humasis, an R&D company based in S. Korea as well. The two sides made this antigen test kit that is said to be capable of detecting the newest COVID-19 variants that originated in Brazil and the U.K.
The rapid test kit can show results in as short as 15 minutes. It will identify the particular antigens of coronavirus that are present in the specimen collected from a person through a sterile nasal swab. Celltrion explained that what sets this kit apart from the other of its kind is that it uses a dual antigen method that can spot both N and S antigens.
“Celltrion will speed up its supply of COVID-19 test kit in the domestic market,” a company official stated. “The firm will submit additional clinical data concerning the test kit to the Ministry of Food and Drug Safety within three months.”
The biopharma company is expecting a surge in global demand for the DiaTrust COVID-19 test kit in the near future. In fact, in the U.S., the kit already received emergency use approval from the Food and Drug Administration (FDA). In April, the agency gave its authorization based on the clinical trial results that Celltrion submitted, and it is now reviewing additional clinical data.
Self-test kit to be marketed after gaining FDA nod
Celltrion was granted conditional approval for DiaTrust last week and to get its formal authorization from S. Korea’s Ministry of Food and Drug Safety. It needs to submit more clinical data within three months, as per the Korea Bio Medical Review.
It was added that the company is planning to supply the COVID-19 test kits via its subsidiary firm, Celltrion Pharm. It is also looking at other distribution outlets such as iMarket Korea.
Meanwhile, Celltrion’s new DiaTrust COVID-19 Ag home test kit was said to have shown results with high accuracy. However, it pointed out that suspected coronavirus patients with an obvious epidemiological connection to infection should get PCR tests at authorized screening centers set up by health authorities because the kits are just a supportive tool.
